Sign inJoin waitlistJoin the waitlist

Ritu Salani

Director, Division of Gynecologic Oncology · UCLA David Geffen School of Medicine/UCLA Medical Center

Credentials: · · · · · · · ·

History

UCLA David Geffen School of Medicine/UCLA Medical Center
Present
UCLA Department of Obstetrics and Gynecology
2020–Present
UCLA David Geffen School of Medicine/UCLA Medical Center
Present

Gynecologic Oncology
Johns Hopkins University School of Medicine
2005–2008
Johns Hopkins Carey Business School
2008
Obstetrics and Gynecology
Emory University School of Medicine
2001–2005
Obstetrics and Gynecology
UCLA David Geffen School of Medicine/UCLA Medical Center
2001–2005
Northeast Ohio Med Univ
1997–2001

Research

Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2023 · 486 citations
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
Nature Genetics · 2013 · 458 citations
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024
Journal of the National Comprehensive Cancer Network · 2023 · 349 citations

David Cohn
44 papers
Floor Backes
42 papers · 21 as a resident
David O'Malley
38 papers
Jeffrey Fowler
37 papers
Larry Copeland
31 papers
Eric Eisenhauer
16 papers · 4 as a fellow
Robert Bristow
16 papers
Beth Karlan
13 papers
Robert Giuntoli
13 papers
Casey Cosgrove
12 papers · 10 as a resident
Christa Nagel
12 papers · 4 as a resident
Kristin Bixel
12 papers

Clinical trials

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)
2011–2017
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
Principal investigator · Completed · Phase 1
Ritu Salani
2010–2015
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Site PI · Recruiting · Phase 3
Verastem, Inc.
2024–2031